The OneFreeze Study

NCT ID: NCT02217254

Last Updated: 2023-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The One Freeze study is a prospective multi-center randomized controlled trial to assess the safety and efficacy of one vs. two cryoablations per pulmonary vein for the treatment of atrial fibrillation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The One Freeze Trial is an investigator-initiated trial that has been developed by the Principals at the University of California, San Francisco (UCSF) and with full participation of the Steering Committee. One Freezel is a prospective multicenter randomized controlled trial with a goal to enroll and randomize a minimum of 90 study participants. Participants will be randomized in a 1:1 ratio to either PVI with a single freeze per pulmonary vein (1F Group) or to PVI with at least two freezes per pulmonary vein (2F Group). The One Freeze study's primary aim is to determine if one 3-minute cryoablation per pulmonary vein results in a lower composite adverse event score as compared to the traditional method of using two 3-minute cryoablations per pulmonary vein.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

two 3-minute cryoablations

two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure

Group Type ACTIVE_COMPARATOR

Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System

Intervention Type PROCEDURE

One 3-minute cryoablation

One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure

Group Type ACTIVE_COMPARATOR

Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pulmonary vein isolation Cryoballoon catheter ablation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Paroxysmal atrial fibrillation
* Age ≥ 18 years
* Life expectancy ≥ 1 year
* Willing and able to return to and comply with scheduled follow-up visits
* Willing and able to provide written informed consent

Exclusion Criteria

* History of \> 5 electric cardioversions
* History of previous pulmonary vein isolation ablation for atrial fibrillation
* History of MAZE procedure
* Left ventricular EF ≤ 35% within the past 12 months
* Mechanical mitral valve
* Single PV \> 30 mm in diameter, unless deemed appropriate by the site PI
* Stroke/TIA within the past 6 months
* Creatinine \> 2.0 mg/dL within the past 6 months
* Pregnancy or desire to get pregnant within the next 12 months
* Current enrollment in an investigation or study of a cardiovascular device or investigational drug that would interfere with this study
* Mental impairment or other conditions, which may not allow the participant to understand the nature, significance and scope of the study
* Any other condition or circumstance that in the judgment of the Clinical Site Investigator that makes the participant unsuitable for the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role collaborator

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Byron K Lee, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, San Francisco

San Francisco, California, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

Montreal Heart Institute

Québec, , Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UC-OF01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.